You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 180 An open-label randomized active-controlled phase ii clinical study to assess efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer

Article metrics

Article menu

Download PDFPDF

Poster
IGCS20_1171
180 An open-label randomized active-controlled phase ii clinical study to assess efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2020 to November 2024

AbstractFullPdf
Nov 20202806
Dec 20201605
Jan 2021402
Feb 2021402
Mar 20211603
Apr 20214008
May 20211002
Jun 2021302
Jul 2021101
Aug 2021004
Sep 2021004
Oct 20219016
Nov 202120013
Dec 20211503
Jan 20221200
Feb 20221608
Mar 20221402
Apr 20224504
May 202225012
Jun 20221804
Jul 20222100
Aug 20222007
Sep 20221707
Oct 20221605
Nov 2022602
Dec 20222303
Jan 20231701
Feb 20231100
Mar 20232103
Apr 20231401
May 20231000
Jun 20232002
Jul 20231704
Aug 20232002
Sep 20231102
Oct 2023603
Nov 20232004
Dec 20233702
Jan 20242603
Feb 20242201
Mar 202428031
Apr 20245007
May 20243001
Jun 20244902
Jul 20242202
Aug 20241506
Sep 20243101
Oct 20241603
Nov 20243301
Total9250207